Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,056.18 -20.42 (-0.50%) Dow
33,740.81 -345.23 (-1.01%) Nasdaq
11,547.63 -36.92 (-0.32%) BTC-USD
23,032.16 -106.84 (-0.46%) CMC Crypto 200
521.33 +278.65 (+114.82%)
VRTX Jun 2023 330.000 call
| Previous close | 21.46 |
| Open | 21.46 |
| Bid | 16.30 |
| Ask | 17.60 |
| Strike | 330.00 |
| Expiry date | 2023-06-16 |
| Day's range | 21.46 - 21.46 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
- Motley Fool
A New Bull Market Could Arrive in February: 3 Stocks to Buy Now
What will it take for a new bull market to begin? The commonly accepted definition of a bull market is when stock prices rise 20% or more above their previous low. A new bull market realistically could be on the way in February.
- Zacks
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).
